

EUR Research Information Portal

Unlocking the value of expanded access ethical, statistical, and policy considerations

Publication status and date:

Published: 10/10/2023

Document Version

Publisher's PDF, also known as Version of record

Citation for the published version (APA):

Polak, T. (2023). *Unlocking the value of expanded access ethical, statistical, and policy considerations*. [Doctoral Thesis, Erasmus University Rotterdam].

[Link to publication on the EUR Research Information Portal](#)

Terms and Conditions of Use

Except as permitted by the applicable copyright law, you may not reproduce or make this material available to any third party without the prior written permission from the copyright holder(s). Copyright law allows the following uses of this material without prior permission:

- you may download, save and print a copy of this material for your personal use only;
- you may share the EUR portal link to this material.


In case the material is published with an open access license (e.g. a Creative Commons (CC) license), other uses may be allowed. Please check the terms and conditions of the specific license.

Take-down policy

If you believe that this material infringes your copyright and/or any other intellectual property rights, you may request its removal by contacting us at the following email address: openaccess.library@eur.nl. Please provide us with all the relevant information, including the reasons why you believe any of your rights have been infringed. In case of a legitimate complaint, we will make the material inaccessible and/or remove it from the website.

UNLOCKING THE VALUE OF EXPANDED ACCESS

**Ethical, Statistical, and
Policy Considerations**



TOBIAS BOY POLAK

Unlocking the Value of Expanded Access
Ethical, Statistical, and Policy Considerations

Tobias Boy Polak

Unlocking the Value of Expanded Access

Statistical, Ethical, and Policy Considerations

ISBN: 978-94-6483-275-4

Lay-out: Publiss | www.publiss.nl

Cover: Publiss | www.publiss.nl

Print: Ridderprint | www.ridderprint.nl

© Copyright T.B. Polak, 2023

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, by photocopying, recording, or otherwise, without the prior written permission of the author.

The printing of this thesis was (financially) supported by: the Department of Epidemiology and Biostatistics, ErasmusMC University Medical Center, Erasmus University Rotterdam; myTomorrows; Servier; The Stichting for Improvement of the Quality of Cardiology; ChipSoft; S.C. De Wijs Topbridge; Brink Bridge; Daiichi Sankyo Nederland B.V. and Drijver Pro Bridge.

Unlocking the Value of Expanded Access Ethical, Statistical, and Policy Considerations

*De waarde van 'expanded access'
verhandelingen over ethiek, statistiek en beleid*

Proefschrift

ter verkrijging van de graad van doctor aan de
Erasmus Universiteit Rotterdam
op gezag van de
rector magnificus

Prof.dr. A.L. Bredenoord

en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op
dinsdag 10 oktober 2023 om 13:00 uur

door

Tobias Boy Polak
geboren te Dordrecht

PROMOTIECOMMISSIE:

Promotor:

Prof.dr. C.A. Uyl – de Groot

Overige leden:

Prof.dr.ir. H. Boersma

Dr. E. Bunnik

Prof.dr. A. Caplan

Copromotor:

Dr. J. van Rosmalen

TABLE OF CONTENTS

| | | |
|------------------|---|--------------|
| Prelude | | 08 |
| Introduction | Background and outline of this thesis | 10 |
| Chapter 1 | Data collection in expanded access: real-world examples Pritelivir for treatment-resistant herpes simplex infections <i>Poster at SSAI/ICHS 2022 and Oral at STI & HIV 2023 (adapted)</i> Tabelecleucel for Epstein-Barr Virus-driven diseases <i>Poster at EHA 2022 and ASCO 2022 (adapted)</i> | 20 |
| Chapter 2 | Expanded access in the Netherlands: prescribing unregistered medicine <i>Nederlands Tijdschrift voor Geneeskunde 2021</i> | 30 |
| Part I ♣ | The clinical merit of expanded access | 44 |
| | Prologue | 47 |
| Chapter 3 | The clinical value of drugs under development in hematological The predictive value of a positive phase II ASH abstract for peer-reviewed publication and progression to phase III <i>Blood 2022 (adapted)</i> Two decades of targeted therapies in acute myeloid leukemia <i>Leukemia 2021 (adapted)</i> | 48 |
| Chapter 4 | Incremental benefits of novel pharmaceuticals in the United Kingdom: A cross-sectional analysis of NICE technology appraisals from 2010 – 2020 <i>BMJ Open 2022</i> Epilogue | 56 74 |
| Part II ♦ | The usage of expanded access data | 78 |
| | Prologue | 80 |
| Chapter 5 | Expanded access as a source of real-world data: An overview of FDA and EMA approvals <i>British Journal of Clinical Pharmacology 2020</i> | 82 |
| Chapter 6 | Real-world data from expanded access programs in health technology assessments: a review of NICE technology appraisals <i>BMJ Open 2022</i> | 100 |
| Chapter 7 | Results from expanded access programs: a review of academic literature <i>Drugs 2023</i> | 124 |

| | | |
|-------------------|---|----------------------------|
| Chapter 8 | Data collection for the sake of data collection Response to Open Peer Commentaries on “Making It Count: Extracting Real World Data from Compassionate Use and Expanded Access Programs” <i>The American Journal of Bioethics 2020</i> Epilogue | 168 172 |
| Part III ♥ | Statistical inclusion of expanded access data | 178 |
| | Prologue | 180 |
| Chapter 9 | Augmenting treatment arms with external data through propensity-score weighted power-priors with an application in expanded access <i>Statistics in Medicine: Under Revision. Preprint: Arxiv 2023</i> | 184 |
| Part IV ♠ | Policy implications and ethical considerations | 216 |
| | Prologue | 218 |
| Chapter 10 | The DRUG Access Protocol: access inequality and European harmonization <i>Lancet Oncology 2022</i> | 220 |
| Chapter 11 | Generating Evidence from Expanded Access Use of Rare Disease Medicines: Challenges and Recommendations <i>Frontiers in Pharmacology 2022</i> | 224 |
| Chapter 12 | The ethics of expanded access research <i>JAMA 2023</i> | 236 |
| Postlude | | 246 |
| | Summary | 248 |
| | Discussion | 253 |
| Appendices | | 264 |
| | Nederlandse samenvatting | 266 |
| | Bibliography | 272 |
| | Portfolio | 275 |
| | About the author | 279 |
| | Acknowledgements (dankwoord) | 280 |



ABOUT THE AUTHOR



Tobias Boy Polak was born on December 30th, 1993 in Dordrecht. In 2011, he completed his gymnasium education with honors at the Lorentz-Casimir Lyceum in Eindhoven. The following year, he started his study in Econometrics and Operations Research at the Erasmus University in Rotterdam. He briefly studied Latin and Greek concurrently at Leiden University, but decided to concentrate on econometrics. He pursued a minor in Applied Statistics, Mathematics, and Informatics in the Social Sciences at the University of Aix-en-Provence. Graduating with honors, Tobias earned his Master's degree in Econometrics and Management Science, focusing on Business Analytics and Quantitative Marketing. His master's thesis was supervised by Prof. Dr. Dimitris Rizopoulos and Dr. Joost van Rosmalen at the Department of Biostatistics at Erasmus Medical Center, and Prof. Dr. Dennis Fok and Prof. Dr. Richard Paap at the Econometric Institute at Erasmus University Rotterdam.

During his studies, Tobias maintained a NOC*NSF Topsport status as a member of the Dutch Youth Bridge Team, winning eight gold medals at Dutch Championships and two silver medals at the World Championships. After concluding his studies and bridge career Tobias started working at myTomorrows, a company specializing in expanded access services. In 2019, he assumed dual roles, serving as both the Director of Real-World Data at myTomorrows and as an external PhD candidate for one day per week. As part of his PhD trajectory, he was invited to attend New York University Grossman School of Medicine as a Visiting Scholar to the Compassionate Use and Preapproval Access (CUPA) working group at the Division of Medical Ethics with Dr. Art Caplan, Dr. Alison-Bateman House, and Dr. Hayley Belli, in 2022. Tobias is a member of CUPA's working group on Ethics & Real-World Evidence. He obtained funding for his research through a HealthHolland Public-Private Partnership Grant and a Prins Bernhard Cultuurfonds Grant to support his Visiting Scholarship in New York City.

Tobias lives in Rotterdam with his first husband. During his leisure time, he enjoys engaging in various sports, attending classical music concerts and theatrical performances. As a hobbyist, he participates in a musical theatre group and a classical choir.

